Subscribe Now Subscribe Today
Science Alert
 
FOLLOW US:     Facebook     Twitter
Blue
   
Curve Top
International Journal of Pharmacology
  Year: 2010 | Volume: 6 | Issue: 4 | Page No.: 326-337
DOI: 10.3923/ijp.2010.326.337
Place of Iron Chelators Like Desferrioxamine and Deferasirox in Management of Hyperoxia-induced Lung Injury; A Systematic Review
Sarah Mousavi, Mojtaba Mojtahedzadeh and Mohammad Abdollahi

Abstract:
Supraphysiological concentrations of oxygen (hyperoxia) is necessary for treatment or prevention of hypoxemic condition, but hyperoxia through activation of oxidative stress pathways and generation of reactive oxygen species directly or indirectly result in lung injury and dysfunction. Many mediators are involved in the pathways to hyperoxic cell death seeming that transition metal ions especially iron promote the generation of the very reactive free radicals which are damaging to cells. Thus concerning the role of iron, a systematic review was conducted by reviewing all papers found from searching keywords of iron, lung injury, oxidative stress or hyperoxia in bibliography databases. Due to different pathways involved in hyperoxia-induced lung injury, several classes of drugs have been tested for example antioxidants, dexamethasone, pentoxifylline, erythropoietin, lisofylline, sildenafile, N-acetyl cysteine, or prostaglandine but some of them were not only successful but caused significant adverse effects. Findings indicate that metal ions especially iron through catalyzing of most reactive free radicals has a key role in oxidative stress process and hyperoxic condition and thus limitation of iron for prevention of hyperoxia-induced injury seems reasonable. Iron chelation has been recently used for conditions without iron overload such as neurodegenerative, infectious, reperfusion injury, cardioprotection. There are some evidences about positive effects of desferrioxamine alone or in combination when tested in animal models of lung injury or in human but they are not convincing. Further studies are necessary to clarify the importance of intervention with desferrioxamine or new long acting oral agent deferasirox and their risk/benefit in hyperoxia-induced lung injury.
PDF Fulltext XML References Citation Report Citation
 RELATED ARTICLES:
  •    A Comprehensive Review of Biochemical and Molecular Evidences from Animal and Human Studies on the Role of Oxidative Stress in Aging: An Epiphenomenon or the Cause
  •    N-acetylcysteine a Novel Treatment for Acute Human Organophosphate Poisoning
  •    Are Iron Chelators Safe to Be Used in Hyperoxia-induced Lung Injury?
  •    Cost and Utilization Study of Antidotes: An Iranian Experience
  •    Future Drugs for Treatment of Acute Respiratory Distress Syndrome
How to cite this article:

Sarah Mousavi, Mojtaba Mojtahedzadeh and Mohammad Abdollahi, 2010. Place of Iron Chelators Like Desferrioxamine and Deferasirox in Management of Hyperoxia-induced Lung Injury; A Systematic Review. International Journal of Pharmacology, 6: 326-337.

DOI: 10.3923/ijp.2010.326.337

URL: https://scialert.net/abstract/?doi=ijp.2010.326.337

 
COMMENT ON THIS PAPER
 
 
 

 

 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 

       

       

Curve Bottom